Branded PPI denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for branded ppi are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna May Deny a Branded PPI as Duplicate Therapy

Aetna's duplicate-therapy denial for a branded proton pump inhibitor (PPI) typically means the plan has identified that another PPI—almost always a generic equivalent or a different branded PPI—is already authorized, dispensed, or covered under the formulary for the same indication. Aetna's formulary generally places generic PPIs at a preferred tier, and a request for a branded product may be flagged as duplicative when a therapeutically equivalent option is available.

This denial is appealable when the prescriber can document a clinical reason why the specific branded product is medically necessary and not substitutable with the covered alternative for this particular patient.

## Federal Appeal Framework

• ACA §2719 / External Review: Available for most non-grandfathered plans within approximately 4 months (180 days) of denial. Expedited review is available when clinical urgency exists.
• ERISA §503 (employer-sponsored plans): Entitles you to the specific formulary criteria and a full-and-fair internal review, including the right to submit clinical evidence.
• Formulary Exception Process: Aetna offers a formulary exception pathway, which is a parallel or preliminary route to a full appeal. A formulary exception can authorize a non-preferred or non-formulary drug when the covered alternative is contraindicated or clinically inadequate for this patient.

## Appeal Process and Timeline

1. Request a formulary exception first — this is often faster than a full appeal. The prescriber submits a request with clinical justification explaining why the specific branded PPI is necessary. 2. Obtain the denial rationale — identify exactly which covered PPI Aetna considers duplicative and what clinical equivalence standard it is applying. 3. Internal appeal — submit within Aetna's appeal deadline (typically 180 days from denial). Standard review is up to 30 days; urgent is 72 hours. 4. External review — if the internal appeal is denied, request independent external review.

## Documentation to Gather

• Diagnosis and indication: Chart documentation of the specific GI condition being treated and its clinical status.
• Prior PPI trial history: Records of any generic or alternative PPIs tried, with dates, duration, and documented inadequate response, adverse effects, or other clinical reason for switching.
• Prescriber medical-necessity letter: A clinical letter explaining why the specific branded PPI is necessary for this patient and why the covered alternative is not appropriate.
• Relevant diagnostic findings: Any endoscopy, pH monitoring, or other diagnostic results supporting the clinical picture and the need for this specific therapy.

## Criteria-Mapping Structure

Obtain Aetna's current formulary and clinical policy for PPI coverage. Address the duplicate-therapy determination directly:

| Aetna Duplicate-Therapy Basis | Appeal Response | |---|---| | Covered PPI alternative identified | [Document clinical reason it is inadequate for this patient] | | Therapeutic equivalence presumed | [Prescriber letter distinguishing clinical need] | | Prior trial of covered alternative | [History of alternative PPI trials with outcomes] | | Diagnosis/indication confirmation | [Chart documentation of GI condition] |

The formulary exception process and the appeal process can run in parallel. File both to preserve your timeline options.